Literature DB >> 2065506

Intra-articular steroids: confounder of clinical trials.

H G Taylor1, P D Fowler, M J David, P T Dawes.   

Abstract

The effect of intra-articular (i-a) steroid injection on ESR and C-reactive protein (CRP) in rheumatoid arthritis (RA) was investigated. One week following injection of 1 or 2 knees there was a significant fall in ESR (p less than 0.0001) and CRP (p less than 0.01) in a cohort of 20 RA patients. The mean drop for both ESR and CRP was 46%. This effect lasted over a variable period up to 6 months. A survey of 50 published drug efficacy studies in RA revealed that, while 44 used ESR and 20 CRP as efficacy measures, 37 neither excluded nor recorded i-a steroid injections during the study. Steroid injections were excluded in 8 studies and recorded in 5, being used as an outcome measure in 2 of these. It is recommended that the frequency with which i-a injections are used in drug efficacy studies is reported and that they are avoided in the 3 months preceding an outcome measurement if ESR or CRP are being used as outcome measures.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065506     DOI: 10.1007/BF02208031

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  54 in total

1.  How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine?

Authors:  J S Dixon; M Greenwood; H A Bird
Journal:  Clin Rheumatol       Date:  1988-06       Impact factor: 2.980

2.  The systemic effects of intra-articular corticosteroid.

Authors:  B E Koehler; M B Urowitz; D W Killinger
Journal:  J Rheumatol       Date:  1974-03       Impact factor: 4.666

3.  A comparison of prednisolone with azathioprine and prednisolone with intramuscular gold in rheumatoid arthritis.

Authors:  H Häntzschel; W Otto; S Arnold; W Seidel; W Krüger; P Winiecki; H A Bird; J S Dixon; G Astbury; V Wright
Journal:  Clin Rheumatol       Date:  1988-06       Impact factor: 2.980

4.  Effect of sulphasalazine on the radiological progression of rheumatoid arthritis.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

5.  Feverfew in rheumatoid arthritis: a double blind, placebo controlled study.

Authors:  M Pattrick; S Heptinstall; M Doherty
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

6.  Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression.

Authors:  P S Hanrahan; G A Scrivens; A S Russell
Journal:  Br J Rheumatol       Date:  1989-04

7.  Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.

Authors:  G Borg; E Allander; B Lund; E Berg; U Brodin; H Pettersson; L Trang
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

8.  Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo.

Authors:  E M Veys; H Mielants; G Verbruggen; J P Grosclaude; W Meyer; A Galazka; J Schindler
Journal:  J Rheumatol       Date:  1988-04       Impact factor: 4.666

9.  Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine.

Authors:  C Astbury; J Hill; H A Bird
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

10.  Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis.

Authors:  T M Hansen; E Dickmeiss; H Jans; T Ingemann Hansen; M Ingeman-Nielsen; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

View more
  2 in total

Review 1.  Perioperative use of intra-articular steroids during the COVID-19 pandemic.

Authors:  Eric Jou; Andrew Kailin Zhou; Jamie Sin Ying Ho; Azeem Thahir
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-09-01

Review 2.  Systemic effects of intra-articular corticosteroids.

Authors:  George S Habib
Journal:  Clin Rheumatol       Date:  2009-02-28       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.